News

• 09/01/10
  Afferent Pharmaceuticals Presents Data Supporting Use of P2X3 Antagonists in Reducing Bone Cancer Pain
  <<click here for release>>

• 08/25/10
  Afferent Pharmaceuticals Announces Data Supporting Potential Utility of Proprietary P2X3 Antagonists in Regulating Bladder Reflexes
  <<click here for release>>

• 1/26/10
  Afferent Pharmaceuticals Names Bruce G. McCarthy, M.D., as CEO
  <<click here for release>>

• 12/16/09
  Roche Licenses First-in-Class Treatments for Chronic Pain to Afferent Pharmaceuticals; Afferent Secures $23 Million in Series A Financing
  <<click here for release>>

Spotlight

Afferent Pharmaceuticals is leading the way with a transformative approach to treating chronic pain
<<click here to learn more>>